These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31838080)

  • 21. Targeted Degradation of the Oncogenic Phosphatase SHP2.
    Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC
    Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising natural products targeting protein tyrosine phosphatase SHP2 for cancer therapy.
    Lu J; Yu D; Li H; Qin P; Chen H; Chen L
    Phytother Res; 2024 Apr; ():. PubMed ID: 38558278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules.
    Guo Z; Duan Y; Sun K; Zheng T; Liu J; Xu S; Xu J
    Eur J Med Chem; 2024 Sep; 275():116579. PubMed ID: 38889611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
    Mitra R; Ayyannan SR
    ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
    LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
    J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of SHP2 in hematopoiesis and leukemogenesis.
    Pandey R; Saxena M; Kapur R
    Curr Opin Hematol; 2017 Jul; 24(4):307-313. PubMed ID: 28306669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
    Tang K; Zhao M; Wu YH; Wu Q; Wang S; Dong Y; Yu B; Song Y; Liu HM
    Eur J Med Chem; 2022 Feb; 230():114106. PubMed ID: 35063735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
    Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
    ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10.
    Xiao P; Zhang H; Zhang Y; Zheng M; Liu R; Zhao Y; Zhang X; Cheng H; Cao Q; Ke Y
    J Exp Med; 2019 Feb; 216(2):337-349. PubMed ID: 30610104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual Allosteric Inhibition of SHP2 Phosphatase.
    Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
    ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment.
    Xiao P; Guo Y; Zhang H; Zhang X; Cheng H; Cao Q; Ke Y
    Oncogene; 2018 Sep; 37(37):5088-5100. PubMed ID: 29795405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies to overcome drug resistance using SHP2 inhibitors.
    Liu M; Gao S; Elhassan RM; Hou X; Fang H
    Acta Pharm Sin B; 2021 Dec; 11(12):3908-3924. PubMed ID: 35024315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of demethylincisterol A
    Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
    Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages.
    Ramesh A; Kumar S; Nandi D; Kulkarni A
    Adv Mater; 2019 Dec; 31(51):e1904364. PubMed ID: 31659802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
    Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
    Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel PROTACs for degradation of SHP2 protein.
    Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
    Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probing the Dynamic Mechanism of Uncommon Allosteric Inhibitors Optimized to Enhance Drug Selectivity of SHP2 with Therapeutic Potential for Cancer Treatment.
    Farrokhzadeh A; Akher FB; Soliman MES
    Appl Biochem Biotechnol; 2019 May; 188(1):260-281. PubMed ID: 30430347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
    Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
    J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.